SCHEMBL96062

SCHEMBL96062

[CH2]c1ccc(C(=O)NCCc2ccc(Cl)cc2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.75
RAB9A P51151 4/20 0.75
MAPT P10636 3/20 0.75
CYP2D6 P10635 2/20 0.75
GAA P10253 2/20 0.75
SMN1; SMN2 Q16637 2/20 0.75
CYP1A2 P05177 2/20 0.75
CYP2C19 P33261 1/20 0.75
GFER P55789 1/20 0.75
MCHR1 Q99705 4/20 0.68
KMT2A Q03164 4/20 0.62
MEN1 O00255 3/20 0.62
CHRM1 P11229 1/20 0.60
HTR2A P28223 1/20 0.60
PSEN1 P49768 1/20 0.60
PSEN2 P49810 1/20 0.60
APH1B Q8WW43 1/20 0.60
NCSTN Q92542 1/20 0.60
APH1A Q96BI3 1/20 0.60
PSENEN Q9NZ42 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1368482 0.86 NPC1 (1.00) NPC1RAB9AMAPTCYP2D6GAA
SCHEMBL8668493 0.86 NPC1 (1.00) NPC1RAB9AMAPTCYP2D6GAA
SCHEMBL1570073 0.84 NPC1 (0.75) NPC1RAB9AMAPTCYP2D6GAA
SCHEMBL27842419 0.84 NPC1 (0.75) NPC1RAB9AMAPTCYP2D6GAA
SCHEMBL1367702 0.84 NPC1 (0.75) NPC1RAB9AMAPTCYP2D6GAA
SCHEMBL2987921 0.84 NPC1 (0.75) NPC1RAB9AMAPTCYP2D6GAA
SCHEMBL1922930 0.84 RAB9A (0.74) NPC1RAB9AMAPTCYP2D6GAA
SCHEMBL28551980 0.84 RAB9A (0.74) NPC1RAB9AMAPTCYP2D6GAA
SCHEMBL95051 0.84 HDAC2 (0.73) NPC1RAB9AMAPTSMN1; SMN2KMT2A
SCHEMBL95043 0.84 MEN1 (0.68) RAB9AMAPTSMN1; SMN2CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB NPC1 2361/4885RAB9A 3886/4885MAPT 4112/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 NPC1 2922/4885RAB9A 2273/4885MAPT 4773/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 NPC1 2922/4885RAB9A 2273/4885MAPT 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.